1-3 of 3 results for subject:Merck
Librarians' tools
- Search time
- 0.301 seconds
- Solr query time
- 0.001 seconds
- Search query
- subject:Merck
- We searched for
- subject_t:Merck OR subject_ses:45422
Type
House
Session
Year
Department
Member
Primary member
Answering member
Legislative stage
Legislation
Subject
More
Publisher
To ask His Majesty's Government what assessment they have made of the impact on jobs in life sciences and access to new medicines of Merck's decision to cancel a planned £1 billion expansion of its UK operations.
To ask His Majesty's Government what assessment they have made of the impact on jobs in life sciences and access to new medicines of Merck's decision to cancel a planned £1 billion expansion of its UK operations.
Asked by
Lord Scriven
(Liberal Democrat)
Answered by
Lord Vallance of Balham
(Labour)
Answering body
Department for Science, Innovation and Technology
Type
Written questions
Status
Answered
Tabled on
11 September 2025
For answer on
25 September 2025
Answered on
25 September 2025
The decision by Merck, or MSD, not to progress its investment, is part of a broader effort by MSD to optimise its resources. It announced in July that it would cut $3 billion per year by 2027 and that 6,000 jobs would go worldwide. MSD continues to employ over 1,600 staff in the UK across other operations, including more than 40 collaborative working agreements with the NHS, the Our Future Health project and UK clinical trials. This decision will not impact UK access to new medicines.
Subjects
Employment; Merck; Life sciences
Date
25 September 2025
Reference
HL10474
House
House of Lords
Type
House of Commons papers; Select Committee written evidence;
Parliamentary committees
Committee
Health Committee
Notes
Report printed as HC 27 2007-08
Subjects
Assessments; Companies; Cost effectiveness; Finance; Licensing; Drugs; NHS; Medical treatments; Patients; Prescription drugs; Public expenditure; Primary care trusts; Prices; National Institute for Health and Care Excellence; Standards; Technology; British Medical Association; Pfizer; Alzheimer's Society; National Osteoporosis Society; Multiple Sclerosis Society; Clinical trials; Royal College of Nursing; Bioindustry Association; British Psychological Society; Cancer Research UK; Diabetes UK; Hepatitis C Trust; British Association for Counselling and Psychotherapy; Help the Aged; Motor Neurone Disease Association; Royal College of Midwives; Amgen Roche; Association of British Healthcare Industries; AstraZeneca; Arthritis and Musculoskeletal Alliance; Breakthrough Breast Cancer; Cancerbackup; Continence Foundation; Cystic Fibrosis Trust; JEC; Medical Technology Group; National Infertility Awareness Campaign; National Childbirth Trust; Myalgic Encephalomyelitis Association; National Rheumatoid Arthritis Society; Royal College of Paediatrics and Child Health; Roche; Sanofi-Aventis; Wyeth; Academy of Medical Sciences; Roy Castle Lung Cancer Foundation; Specialised Healthcare Alliance; Medtronic; American Pharmaceutical Group; Archimedes Pharma; Beat; Bayer Schering Pharma; British Society for Rheumatology; Bristol Myers Squibb Pharmaceuticals; Deltex Medical; Eli Lilly; European Medicines Group; Ethical Medicines Industry Group; FEmISA; Improving Surgical Outcomes Group; Institute for Innovation and Valuation in Health Care; Kidney Cancer UK; Kinetic Concepts; Leukaemia Care; Merck; Myeloma UK; Pelvic Pain Support Network; Rarer Cancers Forum; Royal College of Physicians of Edinburgh; Sirtex Medical; Servier Laboratories; 25% ME Group; Meads, Catherine; Bouder, Frederic; Barkham, Michael; Lofstedt, Ragnar; Simkin, Sandra; Austin, Daphne; Jones, Doris; Hooper, Malcolm; Chalmers, Iain; Hyde, Chris; Lee, Gay; Evans, Imogen; Marshall, Tom; Lee, Michael; Telford, Peter; Walsh, John; Syrett, Keith; Thornton, Hazel; Thomson, David; Woodward, Rose
Date
26 April 2007
Reference
HC 503 2006-07
House
House of Commons
Type
Select Committee reports; House of Lords papers;
Parliamentary committees
Committee
Science and Technology Committee (HL)
Notes
DEBATE;LH 22.03.95
Subjects
British Technology Group; British Gas; Inland Revenue; Higher Education Funding Council for England; Technology; Science; Foreign and Commonwealth Office; Office of Science and Technology; Foreign investment in UK; Alstom; Department of Health; Pfizer; British Aerospace; Department of the Environment; Department of Transport; Department for Education; Chemical Industries Association; Bayer; Elf Oil GB; Medical Research Council; Higher Education Funding Council for Wales; Industrial Development Board for Northern Ireland; Glaxo; Nissan; Invest in Britain Bureau; Ciba-Geigy Chemicals; Hoechst UK; Institute of Biology; Manchester Business School; Lilly Research Centre; Ministry of Agriculture, Fisheries and Food; Kobe Steel Europe; Merck; Crawford, Alex
Commons Library location
Research Sc 500,P
Date
31 October 1994
Reference
HL 36 1993/94
House
House of Lords